about
The next generation of novel therapies for the management of relapsed multiple myeloma.A patient with AL amyloidosis with negative free light chain results.A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis.N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma.Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach.Nutritional counseling improves quality of life and preserves body weight in systemic immunoglobulin light-chain (AL) amyloidosis.Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis.Attitudes about when and how to treat patients with AL amyloidosis: an international survey.Novel strategies for the diagnosis and treatment of cardiac amyloidosis.Serum-free light-chain analysis in diagnosis and management of multiple myeloma and related conditions.Monoclonal IgM-related AL amyloidosis.Genome-wide association study of immunoglobulin light chain amyloidosis in three patient cohorts: comparison with myeloma.Malnutrition at diagnosis predicts mortality in patients with systemic immunoglobulin light-chain amyloidosis independently of cardiac stage and response to treatment.Genome-wide association study of clinical parameters in immunoglobulin light chain amyloidosis in three patient cohorts.Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome.A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis.A practical approach to the diagnosis of systemic amyloidoses.A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis.Proteotoxicity in cardiac amyloidosis: amyloidogenic light chains affect the levels of intracellular proteins in human heart cells.New concepts in the treatment and diagnosis of amyloidosis.The lung in amyloidosis.The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis.The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity.Presentation and outcome with second line treatment in AL amyloidosis previously sensitive to non-transplant therapies.Nutritional status independently affects quality of life of patients with systemic immunoglobulin light-chain (AL) amyloidosis.Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure.Growth Differentiation Factor 15 Is a New Biomarker for Survival and Renal Outcomes in Light Chain (AL) Amyloidosis.Identification and quantification of urinary monoclonal proteins by capillary electrophoresis in AL amyloidosis.Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays.Treatment of IgM-associated AL amyloidosis with the combination of rituximab, bortezomib, and dexamethasone.Patients with AL amyloidosis and low free light-chain burden have distinct clinical features and outcome.Prognostic value of depressed midwall systolic function in cardiac light-chain amyloidosisA staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosisMelphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case–control study on 174 patientsSalvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomideMidregional proadrenomedullin (MR-proADM) is a powerful predictor of early death in AL amyloidosisResponse to bendamustine is associated with a survival advantage in a heavily pretreated patients with AL amyloidosisPrognostication of survival and progression to dialysis in AA amyloidosisUrinary albumin to creatinine ratio in diagnosis and risk stratification of renal AL amyloidosisPatterns of relapse after upfront bortezomib therapy in AL amyloidosis
P50
Q30248534-E0A22B9E-57CD-40E5-86E9-3DA7626BCB47Q33166570-E80BB663-E3B4-4704-AEAC-80C14DE5BFB1Q36862339-C6C40F2B-A1C3-4A11-AE25-082FB310B601Q37456396-696BA105-0FCC-4637-B7BF-CDA2EACADDF3Q37676296-DFF73C09-A499-47AC-9B56-1C321060EA97Q38406601-01C2726F-C7EB-4C85-A81E-80A9A6741986Q38414834-4A2CA5B8-9254-41F1-A2C1-02D90FD11A44Q38600436-B0288601-0EFC-457F-A2F6-B0E93D4DFFF8Q38614967-462425AF-9750-444C-B1DA-740061CBCE52Q38911216-93A0D1A5-16C8-49E8-B541-A12512678E95Q39003127-A260F534-78E6-41F6-8404-6E4ED669E572Q39063150-8BDC0F5A-BC8B-4886-92B1-EEC0C37CF0CDQ39343666-C6146EA8-525C-4A71-82D3-78629DA71654Q40134213-093C7613-4214-48D3-99D6-AA9B252A0DFBQ40184707-967C532D-6A3A-44FF-8505-90F1C5A725BFQ40355511-7A565756-F54F-42AB-913A-A1A006AF8BD4Q41505050-357D3E84-E310-4AEB-939A-33E049F690EFQ44254874-4060BED9-6659-4617-88C3-F4D84D8EA121Q46194651-F6449B74-C2E9-44DC-85B8-1DF886E61E99Q47561519-E7CAE020-3514-487B-8CC5-5FCB567DFEABQ47781293-CFDFB2C7-E932-4722-BC37-CE7478027155Q48121592-773BFBB2-60C0-4162-90EC-A4CB210871BCQ48302753-5EA7224C-0556-4693-AFFA-93D86416E7D8Q48367052-60C980E6-ECCE-4741-849E-62B4FB44DBD6Q48615482-3E6AF6C1-BF49-4D3A-98BC-0AF78B5E0217Q48629376-DBC09636-0F68-45F8-BCD9-D5AA0DD11E48Q49546522-00EA06A6-D5CC-43DF-911C-2A4DDBA588B2Q51039671-A42DCABB-5E48-48BC-AABF-1B896E1DB592Q51084760-4367D2AE-0A02-491F-A931-C9494F063347Q53156031-6A03FAD2-B46A-4017-811C-283850D4B085Q53988051-DFBB9D8A-4FD2-4A7D-B59F-D609068F8A42Q56974552-AD6454E1-8BB4-4F64-A1F2-9F1EF83D7D84Q58029845-371154E7-DB5D-4CC3-8384-904CF47BA093Q58029880-839F424A-7E03-45CB-872B-F4A97303FAF9Q58030111-8386BDD0-9FE3-41B9-A720-C1FD2AB40B52Q58030190-65D0F037-240C-4142-84E9-2A34580760C3Q58125099-FAFED070-E926-454C-99D2-384D5DF32CE0Q58289419-468C26F7-25BB-43B3-977E-EE25F8D81E15Q58293086-4F308FE3-4503-42AD-9BBA-CCDDE56C3E6FQ58424126-36A136C0-20C3-4128-8EEF-899E642662D2
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Paolo Milani
@ast
Paolo Milani
@en
Paolo Milani
@es
Paolo Milani
@nl
Paolo Milani
@sl
type
label
Paolo Milani
@ast
Paolo Milani
@en
Paolo Milani
@es
Paolo Milani
@nl
Paolo Milani
@sl
prefLabel
Paolo Milani
@ast
Paolo Milani
@en
Paolo Milani
@es
Paolo Milani
@nl
Paolo Milani
@sl
P106
P21
P31
P496
0000-0002-2268-9422